相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Identification of WEE1 as a target to make AKT inhibition more effective in melanoma
Omer F. Kuzu et al.
CANCER BIOLOGY & THERAPY (2018)
A Rhodium(III) Complex as an Inhibitor of Neural Precursor Cell Expressed, Developmentally Down-Regulated 8-Activating Enzyme with in Vivo Activity against Inflammatory Bowel Disease
Hai-Jing Zhong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer
Bo Mi Ku et al.
Oncotarget (2017)
WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance
Hongping Zheng et al.
SCIENTIFIC REPORTS (2017)
AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells
Peter John Webster et al.
CELL CYCLE (2017)
WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer
Amanda L. Richer et al.
CANCER RESEARCH (2017)
A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response
Feihong Chen et al.
CANCER LETTERS (2017)
Anticancer Gold(III) Porphyrins Target Mitochondrial Chaperone Hsp60
Di Hu et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress
Kyle C. Cuneo et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
Suzanne Leijen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Targeting WEE1 Kinase in Cancer
Christopher J. Matheson et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
An iridium(III)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent
Hai-Jing Zhong et al.
CHEMICAL SCIENCE (2015)
The role and mechanism of WEE1 on the cisplatin resistance reversal of the HepG2/DDP human hepatic cancer cell line
Weifeng Zhao et al.
ONCOLOGY LETTERS (2015)
Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence
Abdullah A. Osman et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Group 9 Organometallic Compounds for Therapeutic and Bioanalytical Applications
Dik-Lung Ma et al.
ACCOUNTS OF CHEMICAL RESEARCH (2014)
New Strategies for Triple-Negative Breast Cancer-Deciphering the Heterogeneity
Ingrid A. Mayer et al.
CLINICAL CANCER RESEARCH (2014)
γH2AX as a marker of DNA double strand breaks and genomic instability in human population studies
Vanessa Valdiglesias et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2013)
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Daniel Martinez Molina et al.
SCIENCE (2013)
MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells
Jenny M. Kreahling et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Marieke Aarts et al.
CANCER DISCOVERY (2012)
WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe
Philip C. De Witt Hamer et al.
CLINICAL CANCER RESEARCH (2011)
Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome
Lyndsay M. Murrow et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Abrogation of the G(2) Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging Agents
Suzanne Leijen et al.
CURRENT CLINICAL PHARMACOLOGY (2010)
Modulation of the Biological Properties of Aspirin by Formation of a Bioorganometallic Derivative
Ingo Ott et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2009)
Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2009)
New principles in medicinal organometallic chemistry
U Schatzschneider et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2006)
Accelerated luminophore discovery through combinatorial synthesis
MS Lowry et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2004)
分享论文
